Efficacy and Safety of Upadacitinib Monotherapy in MTX-Naive Patients with Early Active RA Receiving Treatment within 3 months of Diagnosis: A Post-Hoc Analysis of the SELECT-EARLY Trial - Research portal of Justus Liebig University Giessen:

Meeting Abstract

Efficacy and Safety of Upadacitinib Monotherapy in MTX-Naive Patients with Early Active RA Receiving Treatment within 3 months of Diagnosis: A Post-Hoc Analysis of the SELECT-EARLY Trial

Authors list: Kapetanovic, Meliha; Andersson, Maria; Friedman, Alan; Shaw, Tim; Song, Yanna; Aletaha, Daniel; Buch, Maya; Mueller-Ladner, Ulf; Pope, Janet

Publication year: 2020

Pages: 1130-1130

Journal: The Journal of Rheumatology

Volume number: 47

Issue number: 7

ISSN: 0315-162X

eISSN: 1499-2752

Conference: 74th Annual Meeting of the Canadian-Rheumatology-Association

Publisher: The Journal of Rheumatology

Citation Styles

Harvard Citation style: Kapetanovic, M., Andersson, M., Friedman, A., Shaw, T., Song, Y., Aletaha, D., et al. (2020) Efficacy and Safety of Upadacitinib Monotherapy in MTX-Naive Patients with Early Active RA Receiving Treatment within 3 months of Diagnosis: A Post-Hoc Analysis of the SELECT-EARLY Trial, The Journal of Rheumatology, 47(7), p. 1130

APA Citation style: Kapetanovic, M., Andersson, M., Friedman, A., Shaw, T., Song, Y., Aletaha, D., Buch, M., Mueller-Ladner, U., & Pope, J. (2020). Efficacy and Safety of Upadacitinib Monotherapy in MTX-Naive Patients with Early Active RA Receiving Treatment within 3 months of Diagnosis: A Post-Hoc Analysis of the SELECT-EARLY Trial. The Journal of Rheumatology. 47(7), 1130.